Storskogen's Q2 Report Approaches - the Cash Flow Story Isn't Turning Yet

Storskogen has scheduled its second quarter 2026 interim report and investor presentation, which should provide the clearest read yet on whether this battered Swedish holding company is approaching an earnings trough - or whether the deterioration has further to run. The answer matters because the stock has been crushed from its peak, falling roughly 80% from a market capitalization near SEK 82 billion to the SEK 14–18 billion range today. A stock that cheap on a nominal basis invites scrutiny, but cheapness alone doesn't make a value investment. The operating data so far this year suggests reasons for caution.

Let me start with the cash flow. Full-year 2025 saw operating cash flow decline to SEK 2,451 million from SEK 3,098 million in the prior year - a drop of more than 20%. The company's own investment story touts persistently strong cash flows and a 74% cash conversion rate, and while 74% is respectable on its face, the declining absolute level is the headline. Then came Q1 2026, where organic EBITA - the earnings measure that strips out acquisitions and disposals to show what the existing portfolio is actually generating - fell 12% on an organic basis. Reported adjusted EBITA was SEK 639 million, down 9% from the prior year quarter, with the margin compressing from 8.8% to 8.1%. The Q1 operating cash flow was SEK 188 million, which is higher than the prior-year quarter but hardly a sign of reacceleration in a business that needs to fund itself through a meaningful debt load.

From a balance sheet perspective, the picture is more concerning. Storskogen's enterprise value sits around SEK 28 billion against a market capitalization of approximately SEK 14–18 billion, implying net debt in the range of SEK 10 billion or more. That is a substantial burden for a business generating mid-SEK 2 billion in operating cash flow per year. The leverage ratio hasn't been disclosed in a way I can verify from the available data, but the gap between enterprise value and market cap alone tells you that debt is a dominant feature of the capital structure. When cash flows are declining and organic EBITA is still contracting, that level of leverage is a liability, not a neutral fact.

Now let's talk about valuation, because that is where the bull case lives. The stock trades at roughly 15 times trailing earnings on one data stream, or 18 times on another - neither is rich. Nordea just raised its target price to SEK 15.90 in late July, maintaining a Buy rating and implying roughly 75% upside from current levels near SEK 9. That kind of analyst target suggests the bank believes the market has overreacted and that the business's diversified portfolio of small and medium-sized companies across trade, industry, and services still generates enough predictable cash flow to justify a higher multiple. S&P Global forecast earnings would bottom in 2024 and has a Stable outlook, which points to the same conclusion: the worst may be behind the company.

There's a problem with that thesis, though. Q1 2026 organic EBITA was still declining 12%, not stabilizing. And the co-founder and major shareholder Daniel Kaplan sold a larger shareholding in June 2026 - a move that may have perfectly rational personal reasons, but one that is hard to read as a bullish signal at this juncture. When an insider sells while organic earnings growth is still negative, the risk that the market is right to be wary starts to feel non-trivial.

The Q2 report should shed light on whether the seasonal pattern - Q1 being the softest quarter, Q2 historically stronger - is holding up. CEO Christer Hansson pointed to gradual improvement through Q1 and a "structurally solid foundation" with a "more focused portfolio and robust balance sheet." Those are reasonable claims in the abstract, but the market has heard management defend the trough thesis before, and the organic EBITA trajectory hasn't yet delivered on it.

All things considered, Storskogen presents a classic value-trap question. The stock is nominally cheap, the debt load is real, cash flows are declining, organic earnings are still deteriorating, and a major insider just sold. Even if the company survives and eventually regains its growth trajectory - which its diversified model and acquisition platform give it a genuine shot at doing - the margin of safety at the current price is questionable given the leverage and the absence of an inflection signal in the operating data. Value investing is not about buying stocks that look cheap on a P/E ratio. It's about buying businesses trading below their intrinsic value where the cash flows, balance sheet, and trajectory support that conclusion. Storskogen doesn't yet meet that test.

I would rate this a Hold. There are better opportunities in the market where cash flows are still growing, leverage is manageable, and the discount to intrinsic value isn't dependent on hoping the trough has finally arrived.